Medscape

FDA Approves 6-Month Formulation of Triptorelin for Prostate Cancer

March 15, 2010 — The US Food and Drug Administration (FDA) has approved a twice-yearly 22.5-mg formulation of triptorelin pamoate injection (Trelstar, Watson Pharmaceuticals, Inc) for the palliative ...
ascopubs.org

Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial

Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...
ascopubs.org

Efficacy of triptorelin in lowering serum testosterone (sT) in patients with advanced prostate cancer.

Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment. Background: Medical castration using gonadotropin-releasing hormone (GnRH) ...
Medindia

Debiopharm Group's Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe

Debiopharm International SA (Debiopharm - http://www.debiopharm.com), a Swiss-based company, part of Debiopharm Group ™, today announced that triptorelin 6-month ...
Medindia

How to Take Triptorelin Pamoate for Injectable Suspension and it's Dose

This medication is a synthetic analogue of gonadotropin-releasing hormone (GnRH) agonist, prescribed for prostate cancer.
Business Wire

First Patients Dosed in Debiopharm's Phase III Trial (LIBELULA) Investigating Debio 4326, a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty

LAUSANNE, Switzerland--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality ...